FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted the NDA on October 17, 2011 seeking approval to market Qnexa in the United States. The FDA accepted the NDA for review on November 3, 2011. The target date for the FDA to complete its review of the Qnexa NDA is April 17, 2012. 

Source:

VIVUS, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study: Only 3% of adults diagnosed as obese or overweight are referred to weight management programs